Febrile Neutropenia: Prevention and Management
Primary Prophylaxis with Growth Factors
For patients at high risk of febrile neutropenia (≥20% risk), use filgrastim 5 mcg/kg daily or pegfilgrastim 6 mg as a single dose per cycle, starting 24-72 hours after chemotherapy completion. 1, 2
Risk Stratification for Growth Factor Use
Use growth factors when:
- Chemotherapy regimen carries ≥20% FN risk (Category 1 evidence) 1, 3
- Dose-dense regimens requiring maintained dose intensity for survival benefit 2, 3
- Patient-specific high-risk factors present, even with <20% regimen risk 1, 3:
- Age ≥65 years
- Poor performance status
- Previous FN episodes
- Bone marrow involvement with tumor
- Poor renal or hepatic function (especially elevated bilirubin)
- Recent surgery or open wounds
- Extensive prior chemotherapy/radiation
Growth Factor Dosing Specifics
Filgrastim (Category 1):
- 5 mcg/kg daily subcutaneously
- Continue through post-nadir ANC recovery to normal levels
- Start 24-72 hours after chemotherapy (never same day) 1
Pegfilgrastim (Category 1):
- 6 mg subcutaneous once per cycle
- Only for regimens given every 2-3 weeks (insufficient data for weekly regimens)
- Start 24-72 hours after chemotherapy 1
Critical caveat: Do not use growth factors concurrently with chemotherapy or radiation therapy 1
Antibacterial Prophylaxis
Fluoroquinolone prophylaxis (levofloxacin 500-750 mg daily OR ciprofloxacin 500-750 mg twice daily) is recommended only for high-risk patients with expected profound, prolonged neutropenia (ANC <100 cells/mm³ for >7 days). 4, 5
When to Use Antibacterial Prophylaxis
High-risk patients requiring prophylaxis:
- Acute myeloid leukemia/myelodysplastic syndrome patients
- Allogeneic HSCT recipients with myeloablative conditioning
- Expected neutropenia duration >7 days with ANC <100 cells/mm³ 4, 5
Do NOT use routinely for:
Levofloxacin is preferred over ciprofloxacin when increased risk of oral mucositis-related viridans streptococcal infection exists 4
Important: Do not add gram-positive coverage (e.g., vancomycin) to fluoroquinolone prophylaxis routinely 4
Management of Established Febrile Neutropenia
Initial Assessment and Risk Stratification
Fever definition: Single oral temperature >38.3°C (101°F) OR sustained >38.0°C (100.4°F) over 1 hour 4
Neutropenia definition: ANC <500 cells/mm³ or expected to decrease to <500 cells/mm³ within 48 hours 6, 4
Use MASCC score for risk stratification:
- High-risk: MASCC score <21
- Low-risk: MASCC score ≥21 6
Empiric Antibiotic Therapy
Initiate antibiotics within 2 hours of presentation 4, 7
High-Risk Patients (MASCC <21)
Monotherapy with antipseudomonal β-lactam:
- Piperacillin-tazobactam (preferred based on lowest mortality and adverse events) 8
- OR cefepime
- OR meropenem/imipenem-cilastatin 8, 9
Add vancomycin when:
- Hemodynamically unstable
- Suspected catheter-related infection
- Skin/soft tissue infection present
- Known MRSA colonization
- High local MRSA prevalence 6, 4
Add aminoglycoside (amikacin) when:
- Suspected resistant gram-negative infection
- Septic shock
- High local resistance rates 8
Low-Risk Patients (MASCC ≥21)
Outpatient oral therapy acceptable:
- Ciprofloxacin 500-750 mg twice daily PLUS amoxicillin-clavulanate 875 mg twice daily 8, 5
- OR moxifloxacin monotherapy 10
Criteria for outpatient management:
- MASCC score ≥21
- No hypotension or organ dysfunction
- Adequate oral intake
- Reliable follow-up within 24 hours 8, 11
Duration of Antimicrobial Therapy
Afebrile, Clinically Stable Patients
Low-risk patients:
- May discontinue antibiotics after 48 hours if blood cultures negative and clinically well, even without marrow recovery 12
High-risk patients:
- Continue antibiotics until ANC >500 cells/mm³ AND afebrile for 24-48 hours 4
Persistent Fever After 4-7 Days
Do NOT routinely add empiric antifungal therapy unless specific risk factors present 5
Consider empiric antifungal (echinocandin, voriconazole, or amphotericin B) when:
- Persistent fever >4-7 days on broad-spectrum antibiotics
- High risk for invasive fungal disease (prolonged neutropenia, prior allogeneic HSCT, high-dose steroids)
- Not receiving mold-active prophylaxis 8, 9
Antifungal Prophylaxis
Oral triazole (posaconazole, voriconazole) OR parenteral echinocandin recommended for:
- AML/MDS patients during induction
- Allogeneic HSCT recipients
- Expected profound, prolonged neutropenia 5
Dosing examples:
- Posaconazole delayed-release tablets: 300 mg twice daily day 1, then 300 mg daily
- Fluconazole: 400 mg daily (for yeast coverage only) 13
Not routinely recommended for solid tumor patients 5
Additional Prophylaxis Considerations
PJP Prophylaxis
- Trimethoprim-sulfamethoxazole 800/160 mg three times weekly
- Continue until CD4+ count >200 cells/μL for >3 months post-chemotherapy 13
HSV/VZV Prophylaxis
- Acyclovir 400-800 mg twice daily OR valacyclovir 500 mg twice daily
- Continue through completion of cancer therapy 13
Key Pitfalls to Avoid
- Never administer growth factors on the same day as chemotherapy - increases adverse events 1
- Do not use prophylactic antibiotics for standard-dose chemotherapy in solid tumors - promotes resistance without survival benefit 1, 5
- Avoid rectal temperatures and examinations during neutropenia 4
- Do not delay antibiotics for diagnostic workup - initiate within 2 hours 4, 7
- Monitor for fluoroquinolone resistance when using prophylaxis - implement systematic surveillance 4
- Do not use sargramostim as first-line - insufficient evidence compared to filgrastim/pegfilgrastim (Category 2B only) 1